NEUMORA THERAPEUTICS, INC. Increase Decrease In Operating Lease Liability
NEUMORA THERAPEUTICS, INC. (NMRA) reported Increase Decrease In Operating Lease Liability of -$138.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$71.00K.
- NEUMORA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$67.00K.
- NEUMORA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$46.00K.
- NEUMORA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was $39.00K.
- NEUMORA THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2025 was -$1.88M.
- NEUMORA THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2024 was -$3.38M.
- NEUMORA THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2023 was -$3.40M.
- NEUMORA THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2022 was -$1.83M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$138.00K 10-Q · filed 2026-08-14 | -$184.00K derived: sum of 3 quarters · filed 2026-08-14 | -$145.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$67.00K 10-Q · filed 2026-05-07 | -$113.00K derived: sum of 2 quarters · filed 2026-05-07 | -$74.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.03M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$7.00K derived: sum of 2 quarters · filed 2026-03-30 | -$965.00K derived: sum of 3 quarters · filed 2026-08-14 | -$1.88M 10-K · filed 2026-03-30 |
| 2025-09-30 | $39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$919.00K derived: sum of 2 quarters · filed 2026-08-14 | -$1.83M 10-Q · filed 2025-11-06 | -$2.73M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$958.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.87M 10-Q · filed 2026-08-14 | -$2.77M derived: sum of 3 quarters · filed 2026-08-14 | -$3.63M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$915.00K 10-Q · filed 2026-05-07 | -$1.81M derived: sum of 2 quarters · filed 2026-05-07 | -$2.67M derived: sum of 3 quarters · filed 2026-05-07 | -$3.49M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$893.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$1.75M derived: sum of 2 quarters · filed 2026-03-30 | -$2.58M derived: sum of 3 quarters · filed 2026-03-30 | -$3.38M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$861.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.68M derived: sum of 2 quarters · filed 2025-11-06 | -$2.48M 10-Q · filed 2025-11-06 | -$3.40M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$822.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$1.62M 10-Q · filed 2025-08-06 | -$2.54M derived: sum of 3 quarters · filed 2025-08-06 | -$3.41M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$802.00K 10-Q · filed 2025-05-12 | -$1.72M derived: sum of 2 quarters · filed 2025-05-12 | -$2.58M derived: sum of 3 quarters · filed 2025-05-12 | -$3.40M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$913.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$1.78M derived: sum of 2 quarters · filed 2025-03-03 | -$2.60M derived: sum of 3 quarters · filed 2025-03-03 | -$3.40M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$869.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$1.69M derived: sum of 2 quarters · filed 2024-11-12 | -$2.49M 10-Q · filed 2024-11-12 | -$3.27M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$820.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$1.62M 10-Q · filed 2024-08-06 | -$2.40M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2023-03-31 | -$801.00K 10-Q · filed 2024-05-07 | -$1.58M derived: sum of 2 quarters · filed 2025-03-03 | ||
| 2022-12-31 | -$781.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$1.83M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | -$1.04M 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |